Table 5.
Comparison between obese and non-obese patients (CHC and HCC)
| Variables | Obese N = 42 N(%) |
Non-obese N = 58 N(%) |
P-value |
|---|---|---|---|
| Age | 60 (36-76) | 57(34-73) | 0.168 |
| Biochemical tests Median(Range), | |||
| ALT (IU/L) | 60 (36-180) | 60(25-103) | 0.817 |
| AST (IU/L) | 93.5(34-310) | 90(25-300) | 0.115 |
| T. Bil (mg/dL) | 2.1(0.6-4.5) | 1.9(0.5-6) | 0.092 |
| Albumin (g/dL) | 3.1(1.6-4.2) | 3.2(1.6-4.2) | 0.262 |
| INR | 1.2(0.8-1.5) | 1.1(0.7-1.5) | <0.001 |
| GGT (IU/L) | 83.5(25-560) | 71(15-500) | 0.043 |
| Fasting Glu (mg/dL) | 190((96-890) | 150 (76-870) | <0.001 |
| Fasting Ins (IU/mL) | 10(6-14) | 7.6 (3.5-15) | <0.001 |
| HbA1c (%) | 8.6(5.2-12) | 6.6 (3.2-13) | <0.001 |
| HOMA-IR | 4.8(1.66-28.5) | 2.37(0.86-32.22) | <0.001 |
| Plt (x109/L) | 140(50-250) | 140 (60-300) | 0.018 |
| Cholesterol (mg/dL) | 220(160-300) | 187 (110-250) | <0.001 |
| TG (mg/dL) | 212(150-300) | 180 (87-220) | <0.001 |
| Tumor marker median(range) | |||
| Serum AFP (ng/mL) | 115(6-1060) | 181(5-560) | 0.229 |
| HCV RNA (viral load copies/IU/L) N(%) | |||
| Low (<100 × 103)n = 21 | 2(4.8) | 19 (32.8) | 0.001 |
| Moderate (100-1000 × 103) n = 56 | 25(59.5) | 31 (53.4) | |
| High (>1000 × 103) n = 23 | 15(35.7) | 8 (13.8) | 0.001 |
| Stage of Fibrosis N(%) | |||
| I+II (n = 17) | 2 (12) | 15 (88) | 0.02 |
| III+IV+ V (n = 83) | 40 (48) | 43 (52) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase, INR, International normalization ratio (for blood clotting); GGT, gammaglutamyl transferase; Glu, glucose; Ins, insulin; HbA1c, glycosylated hemoglobin; HOMA-IR, Homeostasis Model for Assessment of Insulin Resistance; Plt, platelet count; TG, triglycerides; AFP, alpha fetoprotein;